Mangoceuticals, Inc.
MGRXNasdaqCIK 1938046HealthcareFiscal year ends Dec 31
Reports and events: 116 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0920:01 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-046510 |
| 2026-10-0612:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001493152-26-045857 |
| 2026-10-0119:50 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-045341 |
| 2026-08-2121:15 ET | 8-K | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-039724 |
| 2026-08-1321:27 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001493152-26-037873 |
| 2026-08-0420:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-035993 |
| 2026-07-3011:00 ET | 8-K | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035323 |
| 2026-07-0220:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-031917 |
| 2026-05-1920:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001493152-26-024426 |
| 2026-04-0110:31 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001493152-26-014478 |
| 2026-03-1720:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-010526 |
| 2026-02-2321:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-007750 |
| 2026-02-1921:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-007468 |
| 2026-02-0621:30 ET | 8-K | 3.01 Delisting notice | 0001493152-26-005587 |
| 2026-01-2322:07 ET | S-1/A | Registration statement, amended | 0001493152-26-003446 |
| 2026-01-1322:30 ET | S-1 | Registration statement | 0001493152-26-002093 |
| 2025-12-1914:28 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-028463 |
| 2025-12-1912:30 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-028444 |
| 2025-12-1011:40 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-25-027009 |
| 2025-11-1422:17 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001493152-25-023640 |
| 2025-11-1421:37 ET | 10-Q/A | Quarterly report, amendedPeriod 2025-06-30 | 0001493152-25-023566 |
| 2025-11-1412:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-022505 |
| 2025-11-1312:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-022103 |
| 2025-10-2923:28 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-25-019941 |
| 2025-09-3020:59 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001493152-25-016353 |
| 2025-09-1220:33 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-25-013213 |
| 2025-09-0220:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-012557 |
| 2025-08-1420:31 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001493152-25-011994 |
| 2025-08-0413:00 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-011557 |
| 2025-07-2323:24 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-011336 |
| 2025-07-1021:32 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001641172-25-018467 |
| 2025-07-0321:27 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001641172-25-017879 |
| 2025-06-1021:00 ET | 8-K | 3.02 Unregistered sale of equity | 0001641172-25-014545 |
| 2025-05-3020:31 ET | S-1 | Registration statement | 0001641172-25-013052 |
| 2025-05-3023:46 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001641172-25-012917 |
| 2025-05-2321:27 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001641172-25-012336 |
| 2025-05-1520:58 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001641172-25-011047 |
| 2025-05-0621:01 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001641172-25-008878 |
| 2025-04-2513:00 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001641172-25-006122 |
| 2025-04-1721:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001641172-25-005263 |
| 2025-04-1121:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001641172-25-003881 |
| 2025-04-1121:00 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001641172-25-003879 |
| 2025-04-0821:00 ET | 8-K | 3.02 Unregistered sale of equity | 0001641172-25-003245 |
| 2025-04-0220:59 ET | 8-K | 3.02 Unregistered sale of equity | 0001493152-25-011197 |
| 2025-03-2821:00 ET | 8-K | 3.02 Unregistered sale of equity | 0001493152-25-011191 |
| 2025-03-2513:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001641172-25-000525 |
| 2025-03-2021:29 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001641172-25-000085 |
| 2025-03-1913:00 ET | 8-K | 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-25-010875 |
| 2025-02-1922:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-25-007597 |
| 2025-02-1814:00 ET | DEF 14A | Proxy statementPeriod 2025-02-18 | 0001493152-25-007103 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.